NDAORALTABLET, EXTENDED RELEASE
Approved
Jun 2022
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
20
Data completeness
5/8 — Partial
VENLAFAXINE BESYLATE (venlafaxine) by Almatica Pharma is cns. Approved for major depressive disorder, generalized anxiety disorder, panic disorder. First approved in 2022.
Drug data last refreshed 20h ago
Mechanism of Action
CNS. Preclinical studies have shown that venlafaxine and its active metabolite, O-desmethylvenlafaxine (ODV), are potent inhibitors of neuronal serotonin and norepinephrine reuptake and weak inhibitors of dopamine reuptake.
Indications (3)
Worked on VENLAFAXINE BESYLATE at Almatica Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.